MTST (MetaStat) Total Liabilities: $2.28 Mil (As of Feb. 2018)


What is MetaStat Total Liabilities?

MetaStat MTST Total Liabilities is $2.28 Mil as of Feb. 2018.

MetaStat's Total Liabilities for the quarter that ended in Feb. 2018 was $2.28 Mil.

MetaStat's quarterly Total Liabilities declined from Aug. 2017 ($2.12 Mil) to Nov. 2017 ($2.04 Mil) but then increased from Nov. 2017 ($2.04 Mil) to Feb. 2018 ($2.28 Mil).

MetaStat's annual Total Liabilities increased from Feb. 2016 ($2.83 Mil) to Feb. 2017 ($4.06 Mil) but then declined from Feb. 2017 ($4.06 Mil) to Feb. 2018 ($2.28 Mil).

MetaStat Total Liabilities Historical Data

* Premium members only.

The historical data trend for MetaStat's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Total Liabilities Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.87 0.86 2.83 4.06 2.28

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.06 2.18 2.12 2.04 2.28

MetaStat Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MetaStat's Total Liabilities for the fiscal year that ended in Feb. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.08+(0+0.148
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.051+0+0)
=2.28

Total Liabilities=Total Assets (A: Feb. 2018 )-Total Equity (A: Feb. 2018 )
=0.73--1.549
=2.28

MetaStat's Total Liabilities for the quarter that ended in Feb. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.08+(0+0.148
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.051+0+0)
=2.28

Total Liabilities=Total Assets (Q: Feb. 2018 )-Total Equity (Q: Feb. 2018 )
=0.73--1.549
=2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.28 Mil mean?
MetaStat (MTST) has a Total Liabilities of $2.28 Mil as of Feb. 2018. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MetaStat and its competitors.
Is MetaStat's Total Liabilities too high?
MetaStat's current Total Liabilities is $2.28 Mil.
How does MetaStat's Total Liabilities compare to OBMP and NSPX?
MetaStat's Total Liabilities of $2.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MetaStat and its competitors. MetaStat's current Total Liabilities is $2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Total Liabilities of $2.28 Mil. The current Total Liabilities is $2.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MetaStat (MTST), the current Total Liabilities is $2.28 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.